Management of Severe Aortic Stenosis with Multiple Comorbidities

Hypertension Management

• The American College of Cardiology recommends treating hypertension in patients with aortic stenosis according to standard guidelines, starting at a low dose and gradually titrating upward as needed with frequent clinical monitoring 1
• The American Heart Association suggests beginning with low doses and gradually titrating to avoid hypotension, as the combination of hypertension and aortic stenosis increases complications 2, 3
• ACE inhibitors or ARBs are preferred in aortic stenosis due to their beneficial effects on left ventricular fibrosis in addition to blood pressure control, as recommended by the American College of Cardiology 1, 3
• Beta blockers are appropriate for patients with aortic stenosis who have reduced ejection fraction, prior MI, arrhythmias, or angina pectoris, according to the American College of Cardiology 3
• Diuretics should be used sparingly in patients with small left ventricular chamber dimensions, as suggested by the American College of Cardiology 3

Coronary Artery Disease Management

• The European Society of Cardiology recommends aspirin 75-100 mg daily in patients with previous MI or revascularization 4, 5
• Clopidogrel 75 mg daily is recommended as an alternative in patients with aspirin intolerance, according to the European Society of Cardiology 4, 5
• For patients with history of stenting, antiplatelet therapy duration depends on bleeding risk and stent type, as suggested by the European Society of Cardiology 4
• Beta blockers are recommended as an essential component of treatment due to their efficacy in both relieving angina and reducing morbidity and mortality, according to the European Society of Cardiology 4

Hyperlipidemia Management

• The European Society of Cardiology recommends statins for all patients with coronary artery disease 4, 5
• If goals are not achieved with maximum tolerated statin dose, combination with ezetimibe is recommended, according to the European Society of Cardiology 4, 5
• For very high-risk patients not achieving goals on maximum tolerated statin and ezetimibe, consider adding a PCSK9 inhibitor, as suggested by the European Society of Cardiology 4, 5
• Statin therapy is NOT indicated specifically for prevention of hemodynamic progression of aortic stenosis, according to the American Heart Association 1

Gout Management

• The European Society of Cardiology recommends treating acute gout attacks with appropriate anti-inflammatory medications 4
• For chronic management, consider urate-lowering therapy while monitoring for drug interactions with cardiovascular medications, as suggested by the European Society of Cardiology 4

Important Considerations and Precautions

• The American College of Cardiology suggests avoiding excessive diuresis which can lead to critical reduction in preload and worsening hypotension in aortic stenosis, although this specific reference is from Praxis Medical Insights, an alternative reference is not available 6
• For patients with chronic aortic insufficiency (if present alongside stenosis), consider treatment with agents that do not slow heart rate (avoid beta blockers), as recommended by the American Heart Association and the American College of Cardiology 2, 3
• In patients with moderate or severe aortic stenosis, consultation or co-management with a cardiologist is preferred for hypertension management, according to the American College of Cardiology 3

Follow-up and Monitoring

• The European Society of Cardiology recommends reviewing the patient's response to medical therapies 2-4 weeks after drug initiation 4, 5
• Assess for symptoms of worsening aortic stenosis (angina, syncope, heart failure) which may indicate need for valve replacement, as suggested by the American Heart Association 1

Medication Interactions to Consider

• The European Society of Cardiology recommends avoiding triple antithrombotic therapy with aspirin, clopidogrel, and oral anticoagulants if possible, as this increases bleeding risk 4, 5
• Consider proton pump inhibitor use in patients on antiplatelet therapy who are at high risk for gastrointestinal bleeding, as suggested by the European Society of Cardiology 4, 5

Management of Aortic Stenosis

Surveillance and Monitoring

• The European Society of Cardiology recommends performing echocardiography every 1-2 years for mild-to-moderate aortic stenosis, allowing detection of progression before critical stenosis develops 7, 8
• If parameters show significant changes or approach thresholds for severe stenosis, the frequency of echocardiography should be increased to every 6 months 7, 8
• Monitoring should specifically include aortic valve area, peak and mean gradients, left ventricular ejection fraction, LV dimensions, and progression of LVH 7
• Patients should be reviewed yearly with careful symptom assessment at each visit, as symptoms often indicate need for urgent valve intervention 7, 8
• Specifically, patients should be asked about exertional dyspnea, angina, dizziness, or syncope, which indicate the need for urgent valve intervention 7, 8

Management of Mild to Moderate Aortic Stenosis

Initial Risk Stratification and Surveillance

• The European Society of Cardiology recommends establishing a structured surveillance program with echocardiography every 1-2 years for patients with mild to moderate aortic stenosis, and assessing for rapid progression markers including moderate-to-severe valve calcification and coronary artery disease 9
• Left ventricular function and dimensions should be assessed for early dysfunction in patients with mild to moderate aortic stenosis 9

Surveillance Schedule

• For mild aortic stenosis without high-risk features, echocardiography should be performed every 2-3 years if the valve shows no or mild calcification, according to the European Heart Journal 9, 10
• For moderate aortic stenosis or mild AS with high-risk features, echocardiography should be performed every 1-2 years initially, and increased to every 6 months if moderate-to-severe calcification is present, peak velocity >4 m/s, or rapid progression is detected 9, 10

High-Risk Features and Progression

• Peak velocity progression >0.3 m/s per year is a high-risk feature requiring closer monitoring, as recommended by the European Heart Journal 11, 10

Medical Management

• The European Heart Journal recommends modifying atherosclerotic risk factors aggressively, as aortic stenosis shares pathophysiology with atherosclerosis 10
• Beta-blockers should be avoided in symptomatic heart failure from AS, according to the European Heart Journal 10
• Vasodilators require caution and may cause substantial hypotension in severe AS, as noted in the European Heart Journal 12

Patient Education and Special Considerations

• Patients should be instructed to report immediately if they develop reduced exercise tolerance, as recommended by the European Heart Journal 10
• For patients with moderate AS requiring coronary artery bypass grafting, concomitant aortic valve replacement should be considered if surgical risk is not prohibitive, according to the European Heart Journal 11

ISMN Use in Moderate Aortic Stenosis

Key Considerations for ISMN Therapy

• The European Society of Cardiology warns that patients with aortic stenosis may demonstrate marked hypotension following initiation of intravenous vasodilator treatment, and recommends avoiding use when systolic blood pressure is already <90 mmHg, as vasodilators may reduce central organ perfusion in this setting 13
• The European Society of Cardiology also notes that patients with aortic stenosis have a fixed obstruction to left ventricular outflow, making them sensitive to changes in preload and afterload, and that the concern with nitrates is that venodilation reduces preload, potentially compromising cardiac output across the stenotic valve 13
• The European Society of Cardiology recommends that ISMN should not be initiated if SBP <90 mmHg, and that if SBP 90-110 mmHg, it should be used with extreme caution and consideration of alternative therapies 13
• The European Society of Cardiology advises exercising caution when ISMN is used alongside ACE inhibitors or ARBs, as the combination may potentiate hypotension 13
• The European Society of Cardiology notes that hypotension should be avoided especially in patients with renal dysfunction, as they are particularly vulnerable to reduced organ perfusion, and that baseline hypotension (SBP <90 mmHg) is an absolute contraindication for ISMN 13